A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Study of Dofetilide in Patients with Inducible Sustained Ventricular Tachyarrhythmias
- 1 September 1995
- journal article
- clinical trial
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 6 (9) , 687-699
- https://doi.org/10.1111/j.1540-8167.1995.tb00445.x
Abstract
Dofetilide and Ventricular Tachyarrhythmias. Introduction: Dofetilide is a new antiarrhythmic agent with potent Ik blocking properties in vitro. We developed a dose‐ranging, placebo‐controlled study design to define the range of effective doses and to evaluate the clinical electrophysiology of intravenous dofetilide in patients in whom sustained ventricular tachycardia or fibrillation was reproducibly inducible at baseline electrophysiologic testing. Methods and Results: The initial four patients received low doses that were increased in subsequent groups of four if adverse effects were absent. In each group of four patients, one patient was randomly assigned to placebo (double blind). Twenty‐four patients were studied at six incremental loading and maintenance infusion regimens. Dofetilide (0.1 to 8.0 ng/ml.) produced concentration‐related increases in the %δ of QT (r = 0.79, P c (r = 0.60, P =0.02), RR (r = 0.62, P < 0.02), and right ventricular effective refractory period (cycle length 600 msec; r = 0.68, P = 0.04). Placebo produced no changes in any of these measurements. Sustained ventricular tachycardia or ventricular fibrillation was no longer inducible in 1 of 6 patients receiving placebo and 8 of 18 receiving dofetilide (4 to 13 sec nonsustained ventricular tachycardia was induced in 4 of these 8). One patient developed torsades de pointes at a high concentration (5.3 ng/mL). Conclusions: We conclude that: (1) dofetilide produces concentration‐related Ig blocking effects in patients: (2) an incremental dose‐ranging study design aids in identifying the range of doses demonstrating electrophysiologic effects and efficacy; (3) a concomitant placebo group provides important data to assess reproducibility of results over time; and (4) further studies of dofetilide's efficacy and toxicity should be conducted.Keywords
This publication has 24 references indexed in Scilit:
- Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study)The American Journal of Cardiology, 1993
- Suppression of clofilium-induced Early Afterdepolarizations and torsades de pointes by potassium channel openers in vivoJournal of Molecular and Cellular Cardiology, 1992
- Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectorisThe American Journal of Cardiology, 1992
- Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassayJournal of Pharmaceutical and Biomedical Analysis, 1991
- Intravenous 3‐Methoxy‐O‐Desmethyl‐Encainide in Reentrant Supraventricular Tachycardia: A Randomized Double‐Blind Placebo‐Controlled Trial in Patients Undergoing EP StudyPacing and Clinical Electrophysiology, 1991
- Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier.The Journal of general physiology, 1990
- Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery diseaseThe American Journal of Cardiology, 1990
- Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.The Journal of general physiology, 1990
- Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarctsThe American Journal of Cardiology, 1989
- Comparison of immediate versus day to day variability of ventricular tachycardia induction by programmed stimulationJournal of the American College of Cardiology, 1989